A phase 2 clinical trial, published in The New England Journal of Medicine, included 338 adults with a body mass index (BMI) of 30 or greater, or a BMI between 27 and 30, with at least one weight-related comorbidity to assess the efficacy and benefits of retatrutide
Semaglutide, a GLP-1 receptor agonist, is studied extensively in metabolic and weight-related research
Whilst patients taking Rybelsus may occasionally develop urinary tract infections (UTIs), current clinical evidence does not establish a direct causal link between the medication and UTIs
On average, patients using tirzepatide experience up to 22.5% body weight reduction, while semaglutide users see up to 15% weight loss
TUDCA improves bile circulation, aiding digestion and fat metabolism
This may be due to the difference in how the medication is absorbed into the body